Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine presented preclinical data for EDIT-401 at the European Atherosclerosis Society Congress, showing a single dose achieved ~90% mean reductions in LDL-C, Lp(a), and ApoB in non-human primates. The data supports the asset's potential as a best-in-class gene editing medicine for hyperlipidemia, with reductions highly correlated and driven by LDLR upregulation.
Key figures
- Drug Name
- EDIT-401
- Lp a reduction
- ~90%
- Apo b reduction
- ~90%
- Ldl c reduction
- ~90%
- Therapeutic dose
- 1.5 mg/kg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.